Literature DB >> 9484663

Production of milligram concentrations of free prostate specific antigen (fPSA) from LNCaP cell culture: difference between fPSA from LNCaP cell and seminal plasma.

J T Wu1, B W Lyons, G H Liu, L L Wu.   

Abstract

We have established a procedure for the production of milligrams of free PSA (fPSA) from LNCaP cells derived from a human carcinoma of the prostate. By growing LNCaP cells in a serum-free medium in the presence of a synthetic androgen (R1881) and taking advantage of the special design of the Micro-mouse Hollow Fiber Bioreactor, relatively pure fPSA could be obtained. We found that columns containing either Sephacryl S-100 or S-200 could be used to remove the small amount of bovine serum albumin (BSA) and PSA-alpha 1-antichymotrypsin complex (PSA-ACT) from the preparation. More than 90% of the PSA from LNCaP cell cultures are fPSA. Like fPSA from seminal plasma, two fractions of fPSA differing in protease activity can be separated by DEAE-Sepharose chromatography. Based on the band pattern exhibited on the Western blot following sodium dodecyl sulfate-polyacrylamide electrophoresis separation, fPSA from LNCaP contains more inactive PSA isoforms. This was confirmed by chromatofocusing: the isoelectric point (pl) of the major PSA isoforms from the LNCaP cell culture were higher (6.8 and 6.6) than that (6.4 and 6.1) of fPSA from seminal fluid. We conclude that the LNCaP cell culture is a reliable source for obtaining large quantities of pure fPSA both for the preparation of assay calibrators and controls and for studying the difference in fPSA between benign prostate disease and prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484663      PMCID: PMC6808139     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

1.  Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.

Authors:  M Esquenet; J V Swinnen; W Heyns; G Verhoeven
Journal:  Prostate       Date:  1996-03       Impact factor: 4.104

2.  Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.

Authors:  J T Hsieh; H C Wu; M E Gleave; A C von Eschenbach; L W Chung
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

3.  Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.

Authors:  E G Langeler; C J van Uffelen; M A Blankenstein; G J van Steenbrugge; E Mulder
Journal:  Prostate       Date:  1993       Impact factor: 4.104

4.  Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

Authors:  M E Gleave; J T Hsieh; H C Wu; A C von Eschenbach; L W Chung
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

5.  Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.

Authors:  M E Gleave; J T Hsieh; A C von Eschenbach; L W Chung
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

Review 6.  Assay for prostate specific antigen (PSA): problems and possible solutions.

Authors:  J T Wu
Journal:  J Clin Lab Anal       Date:  1994       Impact factor: 2.352

7.  Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer.

Authors:  J T Wu; L Wilson; P Zhang; A W Meikle; R Stephenson
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

8.  Evaluation of free PSA isoforms, PSA complex formation, and specificity of anti-PSA antibodies by HPLC and PAGE-immunoblotting techniques.

Authors:  J T Wu; P Zhang; T Wang; L Wilson; M Astill
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

9.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

Authors:  W J Catalona; D S Smith; R L Wolfert; T J Wang; H G Rittenhouse; T L Ratliff; R B Nadler
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

10.  PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum.

Authors:  J T Wu; P Zhang; M E Astill; L W Wilson; B W Lyons; L L Wu; R Stephenson
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

View more
  2 in total

1.  Impact of assay parameters on the accuracy of free PSA test: source and stability of calibrator, calibration curve fitting, and level of total PSA in the serum.

Authors:  G H Liu; J T Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

2.  Alterations in the serum glycome due to metastatic prostate cancer.

Authors:  Zuzana Kyselova; Yehia Mechref; Mohammad M Al Bataineh; Lacey E Dobrolecki; Robert J Hickey; Jake Vinson; Christopher J Sweeney; Milos V Novotny
Journal:  J Proteome Res       Date:  2007-04-14       Impact factor: 4.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.